PharPoint Research to sponsor Spring 2021 Oncology Investor Conference

PharPoint Research, an award-winning and client-focused contract research organization (CRO), is thrilled to be a CRO Sponsor for the upcoming Spring 2021 Oncology Investor Conference.

About the Oncology Investor Conference

The Spring Meeting of the Oncology Investor Conference will be held from March 29 through April 2, 2021, and feature 4 days of live stream of company presentations and keynote talks, and 5 days of one-on-one meetings.

The event is the preeminent investment event in oncology – for investors seeking to invest in private and public cancer companies, and for cancer related companies seeking investment.  The fall and spring meetings have been held every year since 2017.

The Spring 2021 Conference will feature a track on Immunology and COVID-19 Technologies. There will be no other concurrent presentations taking place during the streaming of this track.

About PharPoint

PharPoint Research is an award-winning contract research organization (CRO) with expertise in oncology. Based in Durham, North Carolina, PharPoint offers clinical operations, project management, biostatistics, and data management services to clients of all sizes. 

PharPoint’s biometric team has supported 150+ oncology studies since 2007, including 2 successful oncology submissions in the last year. PharPoint’s project managers have extensive experience managing trials of all sizes within oncology from Phase I to Phase IV, with team experience including immuno-oncology, autologous vaccine development, and CAR T-Cell therapy. Additionally, PharPoint’s team is capable of exploiting innovations such as de-centralized clinical trials and patient centric modalities. 

 As an agile, client-focused CRO, we’ve championed small pharma and biotech companies from day one. Our consultative nature & transparency in both budgets and timelines make us an award-winning partner. PharPoint maintains a business repeat rate of 95%, and can bring clients results faster, with a biometric timeline averaging 31 days faster than the industry standard. 

Are you a biotech or pharmaceutical company that will be attending the Oncology Investor Conference?

Reserve a spot on our team’s calendars with the form below. We’re looking forward to speaking with you!

Exploring Standard CRO Timeline Benchmarks

Preparing to work with a top biometrics contract research organization and wondering how their promised data management, biostatistics, and medical writing timelines match up to the industry average? To help sponsors dig into these details and ensure the timelines they’re receiving are competitive, we’re providing PharPoint’s typical timelines alongside research that calculates industry standard timelines, when available.

Our hope is that this document can help sponsors set realistic expectations, confidently ask the right questions of their vendors, and ultimately, partner with a top biometrics CRO that keeps their study moving: because patients are waiting.

eBook contents include:

PharPoint’s short eBook, Standard Clinical Trial Timelines: A Sponsor’s Guide to Evaluating Biometrics CROs, includes the below information.

• Standard database build timeline
  • The bigger picture: Considering site identification and study start-up
• Standard mid-study database change timeline
• Standard database lock time
  • Six strategies for a faster database lock
• Evaluating database lock to top line results timeline
  • Ensuring a rapid delivery
• Evaluating database lock to delivery of tables, listings, and figures (TLF) timeline
• Standard clinical study report delivery timeline
• About PharPoint Research